Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-10-10 00:00:00 ET · period of report 2024-10-08 · accession 0001601830-24-000176 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-10-10 | 2024-10-08+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.44M | +6% | +$174.8K |
| DM | 2024-10-10 | 2024-10-08+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.34 | -30.0K | 1.45M | -2% | -$190.2K |
| DM | 2024-10-10 | 2024-10-08+ | RXRX | Secora Michael | CFO | M - OptEx | $0.00 | -78.8K | 416.4K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-10-09 | M | A | 39,375 | $2.22 | 1,465,881 | D | — | — | |
| 2 | Common | Class A Common Stock | 2024-10-08 | M | A | 39,375 | $2.22 | 1,441,506 | D | — | — | |
| 3 | Common | Class A Common Stock | 2024-10-08 | S | D | 15,000 | $6.32 | 1,426,506 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $6.17 to $6.48 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Common | Class A Common Stock | 2024-10-09 | S | D | 15,000 | $6.36 | 1,450,881 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $6.095 to $6.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-10-08 | M | D | 39,375 | $0.00 | 455,760 | D | $2.22 · — to 2030-03-03 | 39,375 Class A Common Stock | (F4) The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-10-09 | M | D | 39,375 | $0.00 | 416,385 | D | $2.22 · — to 2030-03-03 | 39,375 Class A Common Stock | (F4) The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |